Boehringer Ingelheim's Ofev scores FDA nod as first treatment for rare lung disease
admin 9th September 2019 Uncategorised 0Boehringer Ingelheim rode rare lung disease med Ofev to serious sales growth last quarter, and it’s looking to keep that trend going. Could a new, competition-free lung disease indication be the boost the drugmaker is looking for? The FDA Friday green-lighted Ofev in an indication without any other approved drugs.
More: Boehringer Ingelheim's Ofev scores FDA nod as first treatment for rare lung disease
Source: fierce